The approach described here – PAPP-A-resistant IGFBP4 – will inhibit IGF activity even in the presence of the PAPP-A protease and there is some evidence that PAPP-A plays a role in human breast cancer progression (Kuhajda et al, 1985). This evidence concerns the gene IGF1 and breast carcinoma.